ClinPGx Blog (Page 46)

Sign in Subscribe

More issues

New pathway: Vemurafenib Pathway, Pharmacodynamics

We have added a new pathway: Vemurafenib PD pathway to our pathway collections. Vemurafenib (marketed as ZELBORAF) is an oral BRAF inhibitor used to treat late-stage melanoma. It specifically targets the mutant BRAF protein (V600E isoform) that is found in approximately half of all cases of melanoma. Vemurafenib is

PharmGKB welcomes Daniel Klein to the team

We are pleased to welcome curator Daniel Klein to the PharmGKB team. Daniel recently graduated from the University of California, San Diego. His background is physics (specializing in astrophysics) with minors in biology, chemistry, and psychology. During his senior year at UCSD, Daniel worked as a part-time curator for

PGx Look Up Tables

The Translational Pharmacogenetics Project (TPP) is a PGRN-led initiative with the goal to operationalize the work of CPIC by translating widely accepted actionable pharmacogenetics discoveries into real-world clinical practice. TPP creates "look up" tables by gene which contain phenotype and clinical decision support system information based

New Haplotype features on PharmGKB

New features on the Haplotype tab (example: CYP2A6): * Details of the resources used to determine our curated haplotype maps and any important notes regarding the haplotypes are added by our curators. * Previously we only displayed dbSNP rsIDs within haplotypes - now you can view other genetic variants that currently have no

PharmGKB Clinical Annotations Update and New Levels of Evidence

We have launched an update of our Clinical Annotations, assessing new evidence available for each gene variant - drug association. Each Clinical Annotation is written by a PharmGKB curator and assigned a level of evidence. We have recently revised our criteria to provide 6 levels of evidence, from the highest (1A)

Zidovudine Pathway Publication

Zidovudine (ZDV, also known as azidothymidine (AZT)) is an important drug used for treatment of HIV infection. Belonging to the family of nucleoside analog reverse transcriptase inhibitor (NRTI), it is structurally related to the endogenous nucleoside thymidine. ZDV is a prodrug and must be activated by phosphorylation to exert its

Curators' Favorite Papers

The current Curators' Favorite Papers highlight articles about the translation of pharmacogenomics into practice. The article by Johnson et al. describes the design of a customized pharmacogenetics genotyping array. This broad pharmacogenetics panel is built for the personalized medicine programs of the University of Florida and Stanford University [PMID:

New PGRN Featured Project and PI for the Month of September

The PGRN website is featuring a new project and investigator of the month from the PNAT (Pharmacogenomics of Nicotine Addiction Treatment) group.For detailed information, please visit the PGRN website.

The 1200 Patients Project

"The 1200 Patients Project" is a pharmacogenetics (PGx) implementation project established by a team at the University of Chicago who recruited 12 physicians to participate. The project is prospectively recruiting 1200 adults taking 1-6 prescription drugs, who are under the care of one of the participating physicians,

Development of a Customized PGx Genotyping Array using key variants in PharmGKB

The University of Florida and Stanford University are undertaking a joint pharmacogenetics implementation project funded by the NIH, piloted first at Florida and replicated at Stanford. Initially, CYP2C19 genotype will be used to guide clopidogrel therapy, however a customized array of SNPs from 120 genes involved in drug response was